Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02222441 · ClinicalTrials.gov registry record · Phase 1
Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02222441 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 14 participants.
The verdict
NCT02222441, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study is designed to evaluate the potential effect of the moderate CYP3A inducer modafinil and the weak CYP3A inducer pioglitazone on the pharmacokinetics of palbociclib.
Interventions
- DRUG Palbociclib alone
- DRUG Palbociclib plus Modafinil
- DRUG Palbociclib plus pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2014-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02222441
The ClinicalTrials.gov registry entry for NCT02222441 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Palbociclib alone is the first listed.
NCT02222441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02222441 about?
NCT02222441 is a clinical study titled "Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)". This study is designed to evaluate the potential effect of the moderate CYP3A inducer modafinil and the weak CYP3A inducer pioglitazone on the pharmacokinetics of palbociclib.
What is the current status of trial NCT02222441?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2014-10. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02222441?
The interventions under investigation include: Palbociclib alone (DRUG), Palbociclib plus Modafinil (DRUG), Palbociclib plus pioglitazone (DRUG).
Who is sponsoring clinical trial NCT02222441?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.